Comprehensive nursing approach to infliximab infusion therapy

Rheumatoid arthritis (RA) is an immunologically mediated disorder characterized by progressive joint destruction that leads to significant impairment of functioning and quality of life. Its signs and symptoms vary, depending on disease activity. The goals of therapy in patients with RA include a reduction of symptoms, inhibition of structural damage, and improvement in physical function. The paradigm for managing RA calls for adopting a three-pronged strategy that addresses the different aspects of the disease. Infliximab, a biologic response modifier, has been shown to be an effective and safe therapy in patients with RA. Infliximab, in combination with oral or subcutaneous methotrexate, is administered intravenously, most commonly in an office-based setting. As with any intravenously administered protein, infusion-related adverse events have been reported with infliximab; however, such events are infrequent, and slowing the rate of the infusion may reduce their likelihood of occurring. These adverse events can generally be managed easily. Nurses who administer infliximab should have a thorough understanding of the product to prevent or manage adverse events. In this way, they can help ensure the safe delivery of the agent and optimize patient outcomes.